IMW 2019 – aktuelle Daten zu Carfilzomib (Kyprolis®) beim Multiplen Myelom
IMW 2019 – aktuelle Daten zu Carfilzomib (Kyprolis®) beim Multiplen Myelom
IMW 2019 – aktuelle Daten zu Carfilzomib (Kyprolis®) beim Multiplen Myelom
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties